Home > Insider Trading > Filing (0001246360-15-000989)

Filing Details

Accession Number:: 0001246360-15-000989
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-02-19 16:21:09
Reporting Period:: 2015-02-17

Filing Date:: 2015-02-19
Accepted Time:: 2015-02-19 16:21:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
911326	Synageva Biopharma Corp	GEVA	Biological Products, (No Disgnostic Substances) (2836)	561808663

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1277495	Carsten Boess	33 Hayden Ave Lexington MA 02421	Svp, Chief Financial Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-02-17	13,235	$1.70	13,235	No	4	M	Direct
Common Stock	Acquisiton	2015-02-17	29,062	$40.74	42,297	No	4	M	Direct
Common Stock	Disposition	2015-02-17	8,989	$98.85	33,308	No	4	S	Direct
Common Stock	Disposition	2015-02-17	14,750	$99.97	18,558	No	4	S	Direct
Common Stock	Disposition	2015-02-17	16,716	$100.74	1,842	No	4	S	Direct
Common Stock	Disposition	2015-02-17	1,842	$101.69	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2015-02-17	13,235	$0.00	13,235	$1.70
Common Stock	Stock Option (Right to Buy)	Disposition	2015-02-17	29,062	$0.00	29,062	$40.74

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,929		2021-05-25	No	4	M	Direct
15,938		2022-06-27	No	4	M	Direct

Footnotes

The stock option exercise and sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 24, 2014.
The Stock Option granted the reporting person an option to purchase 158,840 shares of the Company's common stock (the "Shares"). 25% of the Shares vested and became exercisable on 05/16/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.
The Stock Option granted the reporting person an option to purchase 45,000 shares of the Company's common stock (the "Shares"). 25% of the Shares vested and became exercisable on 06/27/ 2013 and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $98.34 to $99.32. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $99.36 to $100.35. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $100.45 to $101.37. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.56 to $101.97. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.